Pricing

Iovance Biotherapeutics

4 followers

‌

Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.

Industries

Headquarters

San Carlos, United States

Employees

Links

Org chart

Frederick G. Vogt

Interim CEO, President & General Counsel

Frederick G. Vogt

Collapse

COO

Jean-Marc Bellemin

CFO

Friedrich Graf Finckenstein

Chief Medical Officer

Howard B. Johnson

Chief Business Officer

SVP, Head of Digital & Information Technology

EVP, Human Resources

EVP, Quality

SVP, Research

Vice President, Research Alliances

Jessica Reckner

Senior Director Of Marketing

Nicholas Rojeski

Executive Director, US Marketing

Senior Vice President, Data Management And Solutions

Director, Quality Control Compliance

Stefanie Bulilan

Sr. Director Quality Systems And Compliance

Kerry Elizabeth Wilson Esq.

Executive Counsel

Executive Counsel

Teams

Leadership Team

25 members

Clinical Operations and Research

12 members

Quality Assurance and Compliance

13 members

Information Technology and Data Management

11 members

Finance and Accounting

10 members

Human Resources and Talent Acquisition

7 members

Offices

Similar companies

Roivant Sciences

56 followers

Schrödinger

8 followers

ElevateBio

5 followers

Axsome Therapeutics

4 followers

Vir Biotechnology

3 followers

ImmunityBio

2 followers

Cell Signaling Technology

1 follower

TG Therapeutics

1 follower

Geron

4 followers

Thermo Fisher Scientific

179 followers

Genentech

162 followers

Explore companies